Reconsidering the use of urine drug testing in reproductive settings

Am J Obstet Gynecol MFM. 2023 Dec;5(12):101206. doi: 10.1016/j.ajogmf.2023.101206. Epub 2023 Oct 21.

Abstract

The urine drug test is ubiquitous within reproductive healthcare settings. Although the test can have evidence-based use for a patient and clinician, in practice, it is often applied in ways that are driven by bias and stigma, do not correctly inform decisions about clinical aspects of patient care, and cause devastating ripple effects through social and legal systems. This paper proposes a framework of guiding questions to prompt reflection on (1) the question the clinical team is trying to answer, (2) whether a urine drug test answers the question at hand, (3) how testing benefits compare with the associated risks, (4) a more effective tool for clinical decision-making if the urine drug test does not meet the standards for use, and (5) individual and institutional biases affecting decision-making. We demonstrate the use of this framework using 3 common uses of the urine drug test within abortion care and labor and delivery settings.

Keywords: abortion; abortion restrictions; health inequity; medical decision-making; pregnancy; racism; reproductive rights; substance use; urine drug test.

MeSH terms

  • Clinical Decision-Making
  • Female
  • Humans
  • Pregnancy
  • Substance Abuse Detection* / methods
  • Urinalysis*